The FDA on Thursday released a list of drugmakers that have been delaying generic competition by withholding product samples from generic drug firms using the agency's safety regulations and other strategies. The list, which includes Novartis, Celgene, Johnson & Johnson, Gilead Sciences and 35 other drugmakers, is the Trump administration's latest move to pressure pharmaceutical firms to lower drug prices.
FDA unveils list of drugmakers delaying generic competition
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.